FDA’s Cardio-Renal Division Kicks Off August With Three Approvals
This article was originally published in The Pink Sheet Daily
Executive Summary
The Medicines Co.’s IV therapy Cleviprex plus Novartis’ drug-drug combos, Exforge and Diovan HCT, are approved.